ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on base editing of mRNA transcripts. We discover and develop innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precisely target and correct single point mutations on a mRNA, thus the production of desired and functional protein is restored. Our mission is to discover and develop cutting-edge genetic therapeutics that precisely target and edit single point mutations on RNA transcripts to enable production of desired proteins. We are well-financed with backup from a group of renowned VC funds, and our brand-new laboratory is located in San Diego, California.